We review the clinical trials of angiogenic therapy for myocardial ischemia, focusing on why the results are unsatisfactory in more recent larger and better designed trials. Critical reappraisal of such trials, in view of the pathophysiologic complexity of the angiogenic process at a molecular level, suggests that the strategy of therapies based on a single growth factor protein or gene may not be adequate for optimal therapeutic response.
Get full access to this article
View all access options for this article.
References
1.
RosengartTKLeeLYPatelSRKligfieldPDOkinPMHackettNR. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg1999;230: 466–70.
2.
LosordoDWValePRSymesJFDunningtonCHEsakofDDMayskyM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation1998;98: 2800–4.
3.
SymesJFLosordoDWValePRLathiKGEsakofDDMayskiyM. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg1999;68: 830–6.
4.
ValePRLosordoDWMillikenCEMayskyMEsakofDDSymesJF. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation2000;102: 965–74.
5.
LathiKGValePRLosordoDWCespedesRMSymesJFEsakofDD. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg2001;92: 19–25.
6.
LosordoDWValePRHendelRCMillikenCEFortuinFDCummingsN. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation2002;105: 2012–8.
7.
FortuinFDValePLosordoDWSymesJDeLariaGATynerJJ. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol2003;92: 436–9.
8.
HendelRCHenryTDRocha-SinghKIsnerJMKereiakesDJGiordanoFJ. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect [see comment]. Circulation2000;101: 118–21.
9.
HenryTDRocha-SinghKIsnerJMKereiakesDJGiordanoFJSimonsM. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J2001;142: 872–80.
10.
HenryTDAnnexBHMcKendallGRAzrinMALopezJJGiordanoFJ. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation2003;107: 1359–65.
11.
SchumacherBPecherPvon SpechtBUStegmannT. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease [see comment]. Circulation1998;97: 645–50.
12.
PecherPSchumacherBA. Angiogenesis in ischemic human myocardium: clinical results after 3 years [see comment]. Ann Thorac Surg2000;69: 1414–9.
13.
SellkeFWLahamRJEdelmanERPearlmanJDSimonsM. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg1998;65: 1540–4.
14.
RuelMLahamRJParkerJAPostMJWareJASimonsM. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg2002;124: 28–34.
15.
LahamRJChronosNAPikeMLeimbachMEUdelsonJEPearlmanJD. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol2000;36: 2132–9.
16.
UdelsonJEDilsizianVLahamRJChronosNVansantJBlaisM. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation2000;102: 1605–10.
17.
UngerEFGoncalvesLEpsteinSEChewEYTrapnellCBCannonRO3rd. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol2000;85: 1414–9.
18.
SimonsMAnnexBHLahamRJKleimanNHenryTDauermanH. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation2002;105: 788–93.
19.
GrinesCLWatkinsMWHelmerGPennyWBrinkerJMarmurJD. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris [see comment]. Circulation2002;105: 1291–7.
20.
KutrykMJStewartDJ. Angiogenesis of the heart [review]. Microsc Res Tech2003;60: 138–58.
21.
McMahonJMWellsKEBamfoJECartwrightMAWellsDJ. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther1998;5: 1283–90.
22.
HiromatsuYTodaS. Mast cells and angiogenesis [review]. Microsc Res Tech2003;60: 64–9.
23.
IijimaKYoshikawaNNakamuraH. Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods1996;196: 199–209.
24.
ScapiniPCalzettiFCassatellaMA. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Methods1999;232: 121–9.
25.
GaudryMBregerieOAndrieuVEl BennaJPocidaloMAHakimJ. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood1997;90: 4153–61.
26.
LahamRJRezaeeMPostMSellkeFWBraeckmanRAHungD. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos1999;27: 821–6.
27.
LeeRJSpringerMLBlanco-BoseWEShawRUrsellPCBlauHM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation2000;102: 898–901.
28.
ShalabyFRossantJYamaguchiTPGertsensteinMWuXFBreitmanML. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature1995;376: 62–6.
29.
FongGHZhangLBryceDMPengJ. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development1999;126: 3015–25.
30.
DumontDJGradwohlGFongGHPuriMCGertsensteinMAuerbachA. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev1994;8: 1897–909.
31.
SatoTNTozawaYDeutschUWolburg-BuchholzKFujiwaraYGendron-MaguireM. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature1995;376: 70–4.
32.
SuriCJonesPFPatanSBartunkovaSMaisonpierrePCDavisS. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comment]. Cell1996;87: 1171–80.
33.
MaisonpierrePCSuriCJonesPFBartunkovaSWiegandSJRadziejewskiC. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comment]. Science1997;277: 55–60.
34.
SchattemannGCLoushinCLiTHartCE. PDGF-A is required for normal murine cardiovascular development. Dev Biol1996;176: 133–42.
35.
JainRK. Molecular regulation of vessel maturation [review]. Nat Med2003;9: 685–93.
ChambersRCLeoniPKaminskiNLaurentGJHellerRA. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol2003;162: 533–46.
